In a new study entitled “Effects of Omega-3 Fatty Acid Supplementation on Glucose Control and Lipid Levels in Type 2 Diabetes: A Meta-Analysis”, Researchers led a Systematic analysis of randomized clinical trials investigating the potential therapeutic benefits of omega-3 fatty acids in patients with type 2 diabetes. The study was published in the Open Access Journal Plus one.
Type 2 diabetes Its prevalence is increasing around the world, with lifestyle, particularly diet, cited as the main driver behind the development of the disorder – a condition that is characterized by Hyperglycemia (high blood sugar) as a result of Insulin resistance and Beta cells (unique cells in the pancreas that produce, store and release the hormone insulin) dysfunction.
Big fish and seafood Consumption has been reported to reduce the incidence of type 2 diabetes in the Finnish population, and researchers attribute this effect to this Omega-3 fatty acids – especially the Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA), a group that belongs to polyunsaturated fatty acids (PUFAs)). However, more recently, other studies have reported opposite results, calling into question the proposed benefits of omega-3 for type 2 diabetes patients.
Here the authors carried out a systematic analysis of the published randomized clinical trials To evaluate the evidence of omega-3 benefits in patients with type 2 diabetes and what dosages could have a therapeutic effect. To this end, the team searched the Medline, Pubmed, Cochrane Library, Embase, National Research Register, and SIGLE databases for studies reporting omega-3 and type 2 diabetes.
The team included 20 randomized clinical trials in their analysis. They observed that patients on an omega-3 supplement diet had significantly decreased levels of Triglycerides (a type of fat found in the blood). However, no changes were recorded for a number of parameters, including total blood cholesterol, glycated hemoglobin (HbA1c, a form of hemoglobin that is measured with the aim of determining the average blood sugar concentration over long periods of time), fasting plasma glucose, postprandial plasma glucose, body mass index and body weight. While a high ratio of omega-3 fatty acids EPA / DHA was associated with a decreasing trend for the above parameters, the team did not identify any significant clinical outcome (with the exception of triglycerides). The team postulates that the small sample size, limited number of studies, and short trial duration could be responsible for the lack of statistical significance.
In summary, the authors emphasize that the ratio of EPA / DHA Early intervention with omega-3 fatty acids is a potential parameter for doctors and nutritionists dietary interventions in diabetics.
Print this page